ACBM ACRO BIOMEDICAL CO., LTD.
Services-Amusement & Recreation Services · OTC · SEC CIK 1622996 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-200.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-493.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets12,292.7%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | — | — | — | — | — | — | $0 | $0 |
| SG&A expense | $17,554 | $60,271 | $16,377 | $115,099 | $13,614 | $8,934 | $9,468 | $9,106 |
| Operating income | -$17,554 | -$60,271 | -$16,377 | -$115,099 | -$13,614 | -$8,934 | -$9,468 | -$9,106 |
| Interest expense | — | — | — | — | — | $22,306 | — | $6,110 |
| Pretax income | — | — | $42,526 | -$117,809 | -$15,562 | -$10,301 | -$10,673 | -$10,229 |
| Income tax | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21,356 | -$43,774 | $42,526 | -$117,809 | -$15,562 | -$10,301 | -$10,673 | -$10,229 |
| EPS (diluted) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 60.04M | 60.04M | — | 60.04M | 60.04M | 60.04M | — | 60.04M |
| Balance sheet | ||||||||
| Cash & equivalents | $3,648 | $3,873 | $4,098 | $4,323 | $26 | $251 | $476 | $701 |
| Current assets | $3,648 | $3,873 | $14,098 | $4,323 | $39,626 | $4,851 | $5,076 | $701 |
| Total assets | $3,648 | $3,873 | $14,098 | $4,323 | $53,277 | $25,175 | $31,974 | $38,676 |
| Current liabilities | $448,437 | $431,108 | $401,062 | $436,942 | $370,797 | $329,081 | $326,946 | $317,304 |
| Total liabilities | $448,437 | $431,108 | $401,062 | $436,942 | $370,797 | $329,081 | $326,946 | $324,180 |
| Shareholders' equity | -$444,789 | -$427,235 | -$386,964 | -$432,619 | -$317,520 | -$303,906 | -$294,972 | -$285,504 |
| Shares outstanding | 60.04M | 60.04M | 60.04M | 60.04M | 60.04M | 60.04M | 60.04M | 60.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10,504 | -$49,821 | -$25,377 | -$54,410 | -$93,984 | -$22,531 | -$10,515 | -$6,335 |
| Financing cash flow | $10,279 | $49,596 | $25,152 | $58,707 | $93,759 | $22,306 | $10,290 | $6,110 |
Free plan shows the latest 8 periods; Pro shows all 46 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.